Replies to post #158 on PROLOR Biotech, Inc. (PBTH)

[surf1944]

7:32AM PROLOR Biotech reports positive results from preclinical toxicology study of its reversible-pegylation platform technology (PBTH) 5.10 : Co announces positive results from a preclinical toxicology study designed to assess the safety and tolerability of PROLOR's proprietary long-acting reversible-pegylation technology. The study results demonstrate that RPeg was safe and well-tolerated at high doses following repeated administration in rats. The RPeg platform has been utilized to develop PROLOR's preclinical drug candidate MOD-6030, a GLP-1/Glucagon dual receptor agonist peptide in development for the dual indications of obesity and type 2 diabetes. RPeg can also potentially be applied to a range of peptide and small molecule drugs to increase their duration of action, and it is expected to be especially well suited for use with drugs that must cross the blood-brain barrier.